{
  "docId": "019de076-c164-739c-925e-e97b24983f20",
  "docSlug": "45699c5d62cd10656fd74cee2718d284",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 45 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 45,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "kpi_overview",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 10,
  "notes": "CER stands for Constant Exchange Rates. The slide uses stacked bar charts to show historical performance and 2024 guidance ranges.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-c164-739c-925e-e97b24983f20/13",
  "deckHref": "/decks/019de076-c164-739c-925e-e97b24983f20",
  "deckJsonHref": "/decks/019de076-c164-739c-925e-e97b24983f20.json",
  "deckAnchorHref": "/decks/019de076-c164-739c-925e-e97b24983f20#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.3,
        "x": 0.04,
        "y": 0.815
      },
      "kind": "callout",
      "text": "Strong Total Revenue momentum expected to continue into 2024",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "33dc9d59-3c3d-4b45-810f-79d4f58c2035",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.3,
        "x": 0.35,
        "y": 0.815
      },
      "kind": "callout",
      "text": "2021-2023 Core EPS CAGR of 17%",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "95219b84-d8c7-4515-8e07-82abbe15568b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.3,
        "x": 0.66,
        "y": 0.815
      },
      "kind": "callout",
      "text": "Low single-digit adverse FX impact anticipated on both Total Revenue and Core EPS",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a7b2111a-5ec5-41f5-9c52-f62cebb4c32a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.04,
        "y": 0.22
      },
      "kind": "chart",
      "text": "Total Revenue growth",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "34bb3688-0a37-4b86-b72d-57effc278a97",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.35,
        "y": 0.22
      },
      "kind": "chart",
      "text": "Core EPS growth",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9898e09d-abda-4ba3-b4a0-0da335c634a3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.66,
        "y": 0.22
      },
      "kind": "list",
      "text": "2024 Guidance (CER): Total Revenue and Core EPS growth expectations",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "90194d42-ad79-45a2-8bd3-926c66e75a45",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.04,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1. COVID-19 medicines include Vaxzevria, Evusheld and AZD3152... 2. If foreign exchange rates...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8aefc082-4f3f-4e94-8cef-660c6b18516d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.65,
        "x": 0.04,
        "y": 0.13
      },
      "kind": "title",
      "text": "Underlying business momentum drives strong Total Revenue and Core EPS growth",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "09866719-673c-48e5-8ac9-be4abcb6fdcf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "Track record and FY 2024 guidance (CER)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e208687b-6931-41cf-83ac-f99340551cc0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 26,
      "from": 10,
      "beatId": "43aa94ba-8d07-4798-99cd-6d40ae4b13e2",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The document provides an overview of AstraZeneca's financial results and pipeline success",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}